TENAX THERAPEUTICS, INC. (TENX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 500K 1M 1.5M Q3 '11: 122.9K Q4 '11: 191K Q1 '12: 312.6K Q2 '12: 363.8K Q3 '12: 611K Q4 '12: 1M Q1 '13: 1.1M Q2 '13: 1.2M Q3 '13: 1.1M Q4 '13: 625.5K Q1 '14: 444.9K Q2 '15: 49.3K Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q3 '11 Q1 '12 Q3 '12 Q1 '13 Q3 '13 Q1 '14 Q4 '25 Q2 '26

Gross Profit TTM

-150K -100K -50K 0 50K 100K 150K Q2 '11: 103.2K Q3 '11: 122.9K Q4 '11: 112.7K Q1 '12: 88.3K Q2 '12: 49.3K Q3 '12: 29.9K Q4 '12: 18.5K Q1 '13: 17.6K Q2 '13: 49.6K Q3 '13: 51.9K Q4 '13: 67.8K Q1 '14: 66.6K Q2 '14: -104.1K Q3 '14: -112K Q4 '14: -133.3K Q1 '15: -133.5K Q2 '15: 0 Q3 '11 Q2 '12 Q1 '13 Q4 '13 Q3 '14 Q2 '15

Operating Income TTM

-75M -50M -25M 0 25M 50M 75M Q2 '11: 10.6M Q3 '11: 5.1M Q4 '11: 1M Q1 '12: -3.6M Q2 '12: -8.2M Q3 '12: -7.5M Q4 '12: -6.1M Q1 '13: -5.8M Q2 '13: -5.2M Q3 '13: -5.1M Q4 '13: -6.5M Q1 '14: -7.4M Q2 '14: -16.6M Q3 '14: -17.4M Q4 '14: -19.5M Q1 '15: -20.2M Q4 '16: -64.1M Q1 '17: -54.9M Q2 '17: -56.5M Q3 '17: -59.7M Q4 '17: -9.2M Q1 '18: -11.5M Q2 '18: -12.6M Q3 '18: -12.4M Q4 '18: -6.9M Q1 '19: -6.5M Q2 '19: -6.5M Q3 '19: -5.8M Q4 '19: -8.6M Q1 '20: -7.6M Q2 '20: -7.2M Q3 '20: -7.3M Q4 '20: 9.9M Q1 '21: 31M Q2 '21: 30.8M Q3 '21: 32.3M Q4 '21: -32.7M Q1 '22: -53.8M Q2 '22: -52.9M Q3 '22: -53.7M Q4 '22: 11.1M Q1 '23: 6.8M Q2 '23: 5.2M Q3 '23: 4.4M Q4 '23: -11.3M Q1 '24: -13.7M Q2 '24: -18.6M Q3 '24: -25.3M Q4 '24: -19.5M Q1 '25: -26.9M Q2 '25: -35M Q3 '25: -47.2M Q4 '25: -56.4M Q1 '26: -61.6M Q2 '26: -68.6M Q3 '12 Q2 '14 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Net Income TTM

-90M -60M -30M 0 30M 60M 90M Q2 '11: 10.4M Q3 '11: 4.6M Q4 '11: -405.2K Q1 '12: -10.2M Q2 '12: -15.7M Q3 '12: -16.4M Q4 '12: -15.1M Q1 '13: -10.2M Q2 '13: -9.4M Q3 '13: -8.1M Q4 '13: -10M Q1 '14: -11M Q2 '14: -19.5M Q3 '14: -19.5M Q4 '14: -20M Q1 '15: -19.5M Q4 '16: -54.6M Q1 '17: -46M Q2 '17: -47.7M Q3 '17: -50.7M Q4 '17: -8.8M Q1 '18: -10.9M Q2 '18: -12M Q3 '18: -11.7M Q4 '18: -14.1M Q1 '19: -13.7M Q2 '19: -13.8M Q3 '19: -13.1M Q4 '19: -8.4M Q1 '20: -12.7M Q2 '20: -16.6M Q3 '20: -21M Q4 '20: -23.9M Q1 '21: -45M Q2 '21: -44.6M Q3 '21: -38.5M Q4 '21: -83.4M Q1 '22: -62.4M Q2 '22: -63.5M Q3 '22: -64.4M Q4 '22: -117.2K Q1 '23: 1.2M Q2 '23: 3M Q3 '23: 2M Q4 '23: -12.7M Q1 '24: -15.1M Q2 '24: -17.6M Q3 '24: -23.5M Q4 '24: -17.6M Q1 '25: -24.2M Q2 '25: -31.5M Q3 '25: -43.3M Q4 '25: -52.6M Q1 '26: -57.9M Q2 '26: -64.9M Q3 '12 Q2 '14 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-60M -40M -20M 0 20M 40M 60M Q2 '11: -8.4M Q3 '11: -7.8M Q4 '11: -8.6M Q1 '12: -8.6M Q2 '12: -8.3M Q3 '12: -7.8M Q4 '12: -6.4M Q1 '13: -4.9M Q2 '13: -4.9M Q3 '13: -4.9M Q4 '13: -5.8M Q1 '14: -7.7M Q2 '14: -9.3M Q3 '14: -9.7M Q4 '14: -10.6M Q1 '15: -11.1M Q4 '16: -15.9M Q1 '17: -16.6M Q2 '17: -17M Q3 '17: -14M Q4 '17: -12.1M Q1 '18: -9.7M Q2 '18: -5.3M Q3 '18: -5.6M Q4 '18: -5.5M Q1 '19: -6.1M Q2 '19: -6.8M Q3 '19: -7M Q4 '19: -7.6M Q1 '20: -8.1M Q2 '20: -8.4M Q3 '20: -9M Q4 '20: -9.3M Q1 '21: -9.8M Q2 '21: -9.4M Q3 '21: -10.1M Q4 '21: -10.9M Q1 '22: -10.6M Q2 '22: -12.2M Q3 '22: -12.5M Q4 '22: -11.4M Q1 '23: -10.2M Q2 '23: -7.7M Q3 '23: -6.4M Q4 '23: -5.9M Q1 '24: -9.3M Q2 '24: -11.5M Q3 '24: -12.5M Q4 '24: -14.8M Q1 '25: -16.6M Q2 '25: -19.8M Q3 '25: -25.9M Q4 '25: -35.8M Q1 '26: -38.1M Q2 '26: -46M Q3 '12 Q2 '14 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Free Cash Flow TTM

-18M -12M -6M 0 6M 12M 18M Q2 '11: -8.6M Q3 '11: -8.2M Q4 '11: -9M Q1 '12: -8.7M Q2 '12: -8.3M Q3 '12: -7.9M Q4 '12: -6.5M Q1 '13: -4.9M Q2 '13: -4.9M Q3 '13: -4.9M Q4 '13: -5.8M Q1 '14: -7.7M Q2 '14: -9.3M Q3 '14: -9.7M Q4 '14: -10.6M Q1 '15: -11.1M Q4 '16: -15.9M Q1 '17: -16.6M Q2 '17: -17M Q3 '17: -14M Q4 '17: -12.1M Q1 '18: -9.7M Q2 '18: -5.3M Q3 '18: -5.6M Q4 '18: -5.5M Q1 '19: -6.1M Q2 '19: -6.8M Q3 '19: -7M Q4 '19: -7.6M Q1 '20: -8.1M Q2 '20: -8.4M Q3 '20: -9M Q4 '20: -9.3M Q1 '21: -9.8M Q2 '21: -9.4M Q3 '21: -10.1M Q4 '21: -10.9M Q1 '22: -10.6M Q2 '22: -12.2M Q3 '22: -12.5M Q4 '22: -11.4M Q1 '23: -10.2M Q2 '23: -7.7M Q2 '11 Q4 '12 Q2 '14 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q3 '10: 23.2M Q4 '10: 23.4M Q1 '11: 23.4M Q3 '11: 24.1M Q4 '11: 26M Q1 '12: 29.7M Q3 '12: 1.6M Q4 '12: 1.7M Q1 '13: 1.8M Q3 '13: 2.2M Q4 '13: 4.9M Q1 '14: 10.3M Q3 '14: 27.7M Q4 '14: 28.1M Q1 '15: 28.1M Q1 '24: 1.2M Q2 '24: 2M Q3 '24: 21.2M Q1 '25: 36.6M Q2 '25: 39.6M Q3 '25: 39.7M Q1 '26: 45.2M Q2 '26: 50.9M Q4 '10 Q4 '11 Q4 '12 Q4 '13 Q4 '14 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45.00 -30.00 -15.00 0.00 15.00 30.00 45.00 Q2 '11: -0.45 Q3 '11: -0.65 Q4 '11: -0.85 Q1 '12: -1.13 Q2 '12: -14.43 Q3 '12: -18.40 Q4 '12: -20.74 Q1 '13: -23.13 Q2 '13: -10.48 Q4 '16: -31.24 Q1 '17: -33.38 Q2 '17: -35.33 Q3 '17: -36.05 Q4 '17: -6.27 Q1 '18: -4.78 Q2 '18: -3.94 Q3 '18: -4.12 Q4 '18: -9.03 Q1 '19: -8.52 Q2 '19: -7.52 Q3 '19: -6.80 Q4 '19: -1.36 Q1 '20: -1.41 Q2 '20: -1.36 Q3 '20: -1.21 Q4 '20: -1.01 Q1 '21: -2.27 Q2 '21: -2.14 Q3 '21: -2.11 Q4 '21: -1.93 Q4 '24: -1.15 Q1 '25: 1.69 Q2 '25: 3.25 Q3 '25: 3.04 Q4 '25: -1.33 Q1 '26: -1.40 Q2 '26: -1.48 Q3 '11 Q4 '12 Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.